

PREVENT DISEASES BY VACCINATION

In Service Since 1974



MENINGOCOCCAL POLYSACCHARIDE VACCINE (Group A, C, Y & W135)

Quadri Meningo[™]

DESCRIPTION

Polysaccharide vaccine against cerebrospinal meningitis caused by *Neisseria meningitidis* Group A, C, Y & W135. Quadri Meningo[™] fulfills the specifications of meningococcal polysaccharide vaccine as given in W.H.O. T.R.S. No. 594 (1976), 658 (1981) and 904 (2002). The manufacturing facilities meets the requirement of cGMP guidelines of revised schedule 'M' of Government of India.

INDICATIONS

Prevention of cerebrospinal meningitis caused by *Neisseria meningitidis* Group A, C, Y & W135. Vaccination is recommended in regions of endemic infection, travelers to countries with epidemic meningococcal disease (Hajj pilgrims), household or institutional contacts, military recruits. It is also recommended for subjects living in closed communities and in close contact of patients/carriers of Meningococcal Group A. C. Y & W135.

COMPOSITION

Each dose (0.5 ml) of vaccine contains :

- Purified Polysaccharide of Neisseria meningitidis

PHARMACEUTICAL DOSAGE FORM

Reconstitute the lyophilisate with the entire content of the diluent provided with the vaccine. Shake gently for full reconstitution. The multi dose vaccine vials after opening can be kept at 2-8°C and used for upto 28 days after opening provided sterile techniques have been used for withdrawing vaccine and expiry date have not passed.

ADDITIONAL INFORMATION ON THE STABILITY

The reconstituted vaccine is stable for 1 month when kept at +2°C to +8°C and for 1 week at 25±2°C.

CONTRA-INDICATIONS

- Hypersensitivity to any of the vaccine component.
- Ongoing acute or chronic illness like fever, severe infection, persistent diarrhoea, vomiting.

INSTRUCTION FOR USE

In case vaccine have not been stored in proper cold chain and or crack in vial, the integrity of pellet/powder of vaccine could change. Before using the vaccine check for powder/pellet integrity. The vaccine after reconstitution should be shaken gently and visually inspected for any foreign particulate matter. In the event of either of the above, being observed, discard the vaccine.

As with other vaccines, in rare cases anaphylactic shock may occur in susceptible individual. The mainstay in the treatment of severe anaphylaxis is the prompt use of adrenaline, which can be life saving. It should be used at the first suspicion of anaphylaxis. The vaccinees should remain under observation for not less than 30 minutes for possibility of occurrence of rapid allergic reactions. Hydrocortisone & antihistaminics should also be available in addition to supportive measures such as oxygen inhalation.

DOSAGE AND ADMINISTRATION

- Administer the vaccine (0.5 ml) by intramuscular or subcutaneous route.
 It should under no circumstances be administered intravenously.
- Administration of single 0.5 ml dose of Quadri Meningo¹ elicits a significant bactericidal antibody response in about 100% of subjects. Immunity is conferred for three years.
- The seroconversion rate of children vaccinated under the age of two years is lower for the serogroup C and to lesser extent for the serogroups W135 and Y. However, the seroconversion rate for the serogroup A is acceptable in children from the age of 6 months onwards.

PREGNANCY - BREAST FEEDING

The safety of Meningococcal Polysaccharide Vaccine in pregnant women has not been established. However, it is not categorically contra-indicated during pregnancy or breast - feeding and may be administered where there is a genuine epidemic risk.

SIDE EFFECTS

Reaction to vaccination generally consist of localized injection site reaction (pain, redness), transient hyperthermia, headache, vomiting in children etc.

MEDICATION TO COUNTER POST VACCINATION SIDE EFFECTS

- Give Benadryl/Avil syrup to children upto 10 years of age about half an hour before vaccination. This will prevent vomiting, headache, shivering symptoms which may happen within two hours of vaccination.
- Paracetamol or Ibuprofen cover for 36 hours after vaccination shall decrease the intensity of side effects.

STORAGE

Store between +2°C to +8°C in the refrigerator

PACK SIZE

One, five and ten doses in glass vial with appropriate diluent.

Manufactured & Marketed by :



C-96, Site No. 1, B. S. Road Indl. Area,

Ghaziabad - 201009 (U.P.) INDIA Phone : 0120-4204862, 4157534 Fax : 0120-4340219

Email : bmvaccine@yahoo.com Website : www.biomed.co.in

isite . www.bioined.cc